Spark Therapeutics to Participate in the 35th Annual Cowen and Company Health Care Conference
Print
Alert
SPARK THERAPEUTICS, INC. (NASDAQ:ONCE)
Intraday Stock Chart
Today : Thursday 26 February 2015
Click Here for more SPARK THERAPEUTICS, INC. Charts.
PHILADELPHIA, Feb. 26, 2015 /PRNewswire/ -- Spark Therapeutics (NASDAQ: ONCE) announced today that members of its management team will participate in the Cowen and Company Health Care Conference on Wednesday, March 4, 2015 at 9:40 a.m., Eastern, at the Boston Marriott Copley Place.
To access the live webcast of a Spark Therapeutics presentation from the Cowen conference, please visit the "Upcoming Events" section within the "News and Events" section of the Spark Therapeutics website at www.sparktx.com. A replay of the webcast will be available on the website for 90 days following the conference.
About Spark Therapeutics
Spark is a gene therapy leader seeking to transform the lives of patients suffering from debilitating genetic diseases by developing one-time, life-altering treatments. Spark's initial focus is on treating orphan diseases where no, or only palliative, therapies exist. Spark's most advanced product candidate, SPK-RPE65, which has received both breakthrough therapy and orphan product designation, is in a fully enrolled pivotal Phase 3 clinical trial for the treatment of rare blinding conditions. Spark is leveraging the experience and technology utilized in the development of SPK-RPE65 to address a broad spectrum of blinding conditions, starting with the development of SPK-CHM for the potential treatment of choroideremia, currently in a Phase 1/2 clinical trial. Spark also is establishing a pipeline of gene therapy candidates to treat hematologic disorders and neurodegenerative diseases, including through a global collaboration with Pfizer Inc. around the development and commercialization of its SPK-FIX program for the treatment of hemophilia B. Spark's integrated gene therapy platform builds on two decades of research, development and manufacturing at The Children's Hospital of Philadelphia, including human trials conducted across diverse therapeutic areas and routes of administration. To learn more, please visit www.sparktx.com
